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Abstract 
Atrial fibrillation can be managed with anticoagulation and restoration of normal sinus rhythm 
using direct current cardioversion (DCCV). To reduce the risk of thromboembolism 
anticoagulation pre-and-post DCCV is recommended. This study investigates the cost 
effectiveness of using NOACs compared to warfarin to attain therapeutic anticoagulation 
amongst AF patients pre-and-post DCCV. Propensity score matching revealed no 
statistically significant difference in outcomes from using NOACs and Warfarin. A cost 
minimisation study was performed; demonstrating a cost differential of €209 between those 
administered NOACs and warfarin pre and post DCCV. This study demonstrates how using 
NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients pre-
and-post DCCV is cost effective.  
 
Introduction 
Atrial fibrillation (AF) affects approximately 1-2% of the population worldwide and is a major 
cause of stroke1, which is a major contributor to disability and death. AF is managed using 
anticoagulants (warfarin or new oral anticoagulants (NOACs)) and restoration of normal 
sinus rhythm (NSR) using direct current cardioversion procedure (DCCV). The latter is an 
outpatients procedure whereby synchronized, low-voltage electrical shocks are administered 
to the heart to restore a NSR2. Evidence demonstrates that DCCV is effective and safe with 
success in over 90% of cases whereby NSR is restored3 4. Nevertheless, less than half of 
patients remain in NSR after one year3 4. Factors which influence success and maintenance 
of NSR have been investigated and include duration of AF, cardiac size and function, 
rheumatic heart disease, significant mitral valve disease, delays in conversion, left atrial 
enlargement and older age3. Furthermore, therapeutic anticoagulation for 3-4 weeks prior to 
DCCV is recommended to reduce the risk of thromboembolism 3 5 from 3-5% 5-8 to less than 
1%3 9 10. The traditional anticoagulant prescribed is warfarin, and while this is effective in 
reducing the risk of thromboembolism it has been found to be unpredictable, thus requiring 
monitoring and adjustments in dosage11 which can contribute to delays in performing DCCV. 
This can have a negative impact on the success of DCCV and maintenance of NSR in the 
longer term3.  NOACs have emerged as safe and effective alternatives to warfarin [12-14], 
eliminating the need for monitoring and dose adjustments3. While these advantages of 
NOACs make them attractive for patients and clinicians, their high drug cost relative to 
warfarin means their reimbursement in public health care systems may be difficult. This 
study aims to determine the cost impact of using NOACs compared to warfarin to attain 
therapeutic anticoagulation for patients with AF pre and post a DCCV. 
 
Ireland is chosen as a case study for this cost minimisation analyses as it represents a 
typical public health care system with a substantial reimbursement system for 
pharmaceutical drugs15 16. It is expected that by 2050 the population aged over 65 years will 
double to 1.4 million17.  While, somewhat behind its neighbours Ireland has the opportunity 
to implement cost effective policies and initiatives when managing services for the silver 
economy. Furthermore, while several NOACs (Apixaban, Dabigatran and Rivaroxaban) have 
been deemed cost effective in Ireland by the National Centre of Pharmacoeconomics 
(NCPE) budget implications and concerns over safety have hindered their use18-20. 
                                                                      Ir Med J Nov/Dec 2016; 109; 9 (480) 
Article link  
Methods 
Evidence from the Cardiology Department at Cork University Hospital was employed where 
there is an advanced nurse practitioner led DCCV service. CUH acts as a regional centre for 
secondary and tertiary care for the catchment population of 550,000 served by the HSE 
Southern area and a supra-regional centre for a total a population of 1.1 million21. A sample 
of 178 patients was derived from a registry in the Cardiology Department at CUH over two 
six month periods between 2013 and 2014. No patient in the study had to have either 
Warfarin or NOAC discontinued for an emergency situation. This is a rare occurrence in real 
life with both NOACs and Warfarin and would be unlikely to have an impact on costs. In the 
sample, 80% were male with an average age of 62 years (std. dev. 10.9). The minimum 
CHADS2VASC Score was 0 and the maximum was 4 with modal category of 1. NSR was 
achieved in 91% of cases (8% remained in AF and 1% moved to atrial flutter (AFF)). The 
average waiting time to receive cardioversion was 66 days (std. dev. 48). In the sample, 88 
patients were administered warfarin and 90 received a NOAC (76 received dabigatran and 
14 rivaroxaban). Amongst those receiving warfarin, 67 were male with an average age of 
65.2 years (std. dev. 9.85). The modal CHADS2VASC score was 1 and 58% of the sample 
had CHADS2VASC score greater than or equal to 2. Post DCCV, NSR was achieved in 90% 
of cases and the average waiting time was 91 days for patients prescribed warfarin (std. dev. 
54). After two months, only 65% remained in NSR.  In the NOAC sample there were 76 
males and 15 females. The average age in that sample was 59.7 years (std. dev. 11.2). The 
modal CHADS2VASC score was 0 and 42% of patients had a CHADS2VASC scores greater 
than or equal to 2. NSR was achieved in 92% of cases and the average waiting time for 
DCCV was 42 days (std. dev. 23). After two months, only 62% of patients remained in NSR.  
 
A cost minimisation analysis (CMA) was undertaken to reveal the costs associated with 
warfarin compared to the NOACs for DCCV for AF patients. A CMA is a type of economic 
evaluation wherein two or more interventions are compared22. Here the administering of 
NOACs is compared to the administering of warfarin pre and post a DCCV. A key 
assumption of such an evaluation is that the outcomes of the different programmes are 
broadly equivalent22, thus only the programme which delivers the outcome at the least cost 
is preferred. To conduct the CMA there were two stages. Firstly, to determine there was no 
expected difference in outcome (i.e. in achieving NSR after DCCV) between those 
administered warfarin and NOACs, propensity score matching was performed.  The nearest 
neighbour matching method was employed to estimate standard errors to determine if the 
difference in outcome (i.e. achieving NSR) is statistically different between the two 
treatments. Secondly, a micro costing study was performed to reveal the costs associated 
with using NOACs compared to warfarin for patients with AF pre and post a DCCV. This 
involved identifying, measuring and valuing the associated resource use. To identify and 
measure the costs an observation study was performed and expert opinion was elicited in 
CUH in January 2014. To value the costs, secondary data from previous studies was used 
where available; public sector salary scales were used to value staff costs and overheads as 
per HIQA recommendations23; and drug costs were sourced from the Primary Care 
Reimbursement Service (PCRS) and published sources.  
 
Results 
Propensity score matching was performed to determine whether there was no expected 
difference in outcome (i.e. in achieving NSR after DCCV) between those administered 
warfarin and NOACs. Using nearest neighbour matching method the standard errors 
indicated that the difference in outcome (i.e. achieving NSR) is not statistically different 
between those receiving warfarin and NOACs immediately post DCCV (n treatment =90; n 
control = 42; std error = 0.080; test statistic -0.069). Maintaining NSR two months post 
DCCV was also assessed. Again the propensity score matching found no clinical difference 
between warfarin and NOACs with respect to achieving and maintaining NSR after two 
months (n treatment =90; n control = 42; std error = 0.115; test statistic 0.296).  
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Having determined that there was no statistically significant difference in outcomes after 
DCCV between those for whom therapeutic anticoagulation was achieved with warfarin and 
NOACs, a CMA was performed to indicate which programme is the most cost effective.   
A micro costing study was performed to reveal the costs associated with anticoagulation 
between people on warfarin and NOACs receiving DCCV. This involved identifying, 
measuring and valuing the associated resource use. The costs were categorised into 
monitoring costs and drug costs. Monitoring costs applied to warfarin only and included 
consumables for testing INR levels (nitrile gloves, sterile cotton wool balls, injection swabs, 
needle, monovette and tape), laboratory analysis (staff costs, innovin, cuvettes, and analyser 
tubes), telephone communications (relaying results), staff costs (clerical, nurses, 
phlebotomy) and overheads. Resources were measured using a combination of primary data 
(observation study, CUH January 2014) and secondary data24. Following HIQA23 guidelines 
resources were valued using market values and HSE salary scales. 
 
 
 
The monitoring clinic costs per patient, per visit consist of taking blood €1.19 (as per 
HIQA24); laboratory analysis €1.18; telephone costs €1.05; staff €14.85 and overheads 
€3.30. Thus the total cost of the monitoring clinic per patient per visit is €21.56. (This is 
comparable with the results found in another hospital based Warfarin monitoring clinic in 
Ireland25). Given that the average wait for DCCV is 90.829 days, which is equivalent to 12.98 
weekly visits. At €21.56 per visit, the cost of monitoring prior to DCCV for those administered 
warfarin is €279.76. 
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The cost of pharmaceutical drug costs was sourced from the Medicines Management 
Programme review of oral anticoagulants for stroke prevention with AF20. The price per day 
for dabigatran is €2.54 (150mg and 110 mg) and rivaroxaban is €2.29 (20mg and 15 mg). 
The cost of warfarin was sourced from Barry18 as €0.076 per day (adjusted for inflation).  
Evidence from the registry revealed average (weighted) waiting time for NOAC patients 
waiting for DCCV is 41.77 days and weighted cost is €2.50 per day. Thus the average 
pharmaceutical drug costs associated with NOACs prior to DCCV is €104.48. The average 
pharmaceutical drug cost per patient for warfarin (90.829 day wait) is €6.91.  
Patients receiving DCCV should remain on anticoagulants up to six weeks post procedure. 
This amounts to additional pharmaceutical costs of €105.05 for patients administered 
NOACs. For patients adminstered warfarin the pharmaceutical cost is €3.20 monitoring costs 
€129.36 (6 visits). Thus the total cost for those administered NOACs for anticoagulation 
before and after DCCV is €209.53 and for warfarin is €419.23. The incremental cost is 
€209.70. Administering NOACs being almost 50% less expensive than warfarin when weekly 
monitoring and pharmaceutical drugs costs are accounted for. 
 
 
 
Discussion 
Having matched the samples from the registry data there was no statistically significant 
difference in achieving NSR between those administered warfarin and NOACs. With respect 
to costs, the average costs for those administered NOACs are €209 less than for those 
administered warfarin pre and post DCCV. This is despite the daily drug costs for NOACs 
being 32 times more expensive than warfarin. However, the waiting time for DCCV is less 
amongst those administered NOACs compared to warfarin and there are no monitoring 
                                                                      Ir Med J Nov/Dec 2016; 109; 9 (480) 
Article link  
requirements – monitoring costs represent 98% of the costs associated with those 
administered warfarin.   
 
There are limitations to this study which centre on the data employed, particularly pertaining 
to sample size and lack of randomisation. In addition, the authors are cognisant of the 
variability in the results owing to the real world nature of the data. However, should waiting 
times be improved upon it would reduce the cost associated with DCCV when administering 
NOACs further. This analysis considers patients who were not previously administered an 
anticoagulant. Given the demographics of the patient population it is likely that patients with 
a higher risk of stroke owing to AF may require long term anticoagulation post DCCV. Long 
term cost effectiveness of NOACs compared to warfarin has been investigated by decision 
makers on a country by country basis. This analysis revealed that administering NOACs pre 
and post a DCCV can reduce costs relative to administering warfarin without impacting 
outcomes; thus can be considered cost effective.  
 
Since the data was collected, new guidance on preferred prescribing has emerged in 
Ireland. Despite three NOACs being considered cost effective, warfarin remains the first line 
therapy for stroke prevention in AF in Ireland20. Apixaban is the first line option when 
warfarin is not considered suitable owing to an allergy or labile INR levels20. As populations 
age and AF becomes more prevalent, patient demands for the latest drug or technology 
increase thus placing increasing pressures on the delivery of health care.  Ensuring the right 
patient receives the right treatment in a cost effective manner continues to be a challenge. 
This study demonstrates how economic evaluations can be used to inform resource 
allocation decisions in clinical settings.  
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